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Abstract Agonists at the benzodiazepine-binding site of
ionotropic γ-aminobutyric acid (GABAA) receptors are in
clinical use as hypnotics, anxiolytics, and anticonvulsants
since the early 1960. Analgesic effects of classical
benzodiazepines have occasionally been reported in certain
subgroups of patients suffering from chronic pain or after
spinal delivery through intrathecal catheters. However,
these drugs are generally not considered as analgesics but
should in fact be avoided in patients with chronic pain.
Recent evidence from genetically modified mice now
indicates that agents targeting only a subset of benzodiaz-
epine (GABAA) receptors should provide pronounced
antihyperalgesic activity against inflammatory and neuro-
pathic pain. Several such compounds have been developed
recently, which exhibit significant antihyperalgesia in mice
and rats and appear to be devoid of the typical side-effects
of classical benzodiazepines.
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More than 40 years ago, the so-called gate control theory of
pain proposed by Ronald Melzack and Patrick Wall [1] has
postulated that inhibitory neurons in the spinal cord dorsal
horn would control the transmission of nociceptive (“pain”)
signals coming from the periphery through the spinal cord
to higher brain areas where pain becomes conscious. Since
these early days, the nature of this inhibitory control has
been unraveled and γ-aminobutyric acid (GABA) and
glycine have been identified as the two fast inhibitory
neurotransmitters in the spinal dorsal horn. Subsequently, it
was proven that pharmacological blockade of GABA or
glycine receptors in the spinal dorsal horn provokes pain
sensation in animals as well as in humans [2, 3]. More
recently, several groups could also demonstrate that a
reduction in GABAergic and glycinergic neurotransmission
occurs naturally in the course of inflammatory and
neuropathic pain [4]. Accordingly, restoring the function
of inhibitory neurotransmission in the spinal dorsal horn
should be a rational approach to the treatment of chronic
pain conditions. However, attempts to translate the gate
control theory into novel pharmacotherapies of pain have
failed miserably. This is particularly surprising because
GABAA receptors are among the most successfully
exploited drug targets. Drugs acting at GABAA receptors
include the benzodiazepine site agonists (“benzodiaze-
pines”) which facilitate the action of GABA at GABAA
receptors and which are widely used clinically for their
sleep promoting, anxiolytic, and anticonvulsive effects.
However, although anecdotal evidence exists for a pain-
relieving effect in certain groups of patients, the vast
majority of reports indicate that benzodiazepines do not
exert a clear analgesic effect in patients or in human
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experimental pain models [5]. This is again surprising for
several reasons. Benzodiazepine-sensitive GABAA recep-
tors are found in the spinal terminals of primary nociceptors
as well as at other sites in the pain pathway including
neurons in the superficial layers of the spinal dorsal horn
[6], a pivotal structure for the processing of pain signals.
Local spinal injection of benzodiazepines (mainly diazepam
or its short acting and rather hydrophilic derivative
midazolam) is antinociceptive both in animal experiments
[7-9] and in human patients [10, 11]. Part of this
discrepancy is probably due to the fact that experimental
studies hardly discriminated between acute analgesic (anti-
nociceptive) effects (e.g. [12]) and a reversal of patholog-
ically increased pain sensitivity (antihyperalgesia). In fact, a
recent study showed that intrathecal injection of diazepam
in mice normalized pain thresholds in mice suffering from
increased pain sensitivity due to peripheral inflammation or
nerve damage but had no effect on acute nociceptive pain
[13]. It is however still surprising that classical benzodia-
zepines are not analgesic in patients with chronic pain who
usually also show pronounced hyperalgesia.
What are possible explanations for this apparent dis-
crepancy? Animal studies on pain largely rely on the
assessment of nociceptive withdrawal reflexes upon expo-
sure of a paw or the tail to a painful stimulus (heat, cold, or
mechanical stress) as a measure of changes in pain
sensitivity. Positive results from animal studies could hence
be confounded by sedation, muscle relaxation, or reversal
of anxiety-induced hyperalgesia. It is also possible that pain
relief might occur only at doses sufficiently high to provoke
at the same time strong sedation making it extremely
difficult to distinguish analgesia from sedation. Alterna-
tively, if benzodiazepines were in fact analgesic after spinal
but not after systemic application, pronociceptive effects at
supraspinal sites might antagonize spinal antihyperalgesic
actions. Such pronociceptive effects have indeed been
reported after intracerebroventricular injection of midazo-
lam [8].
Fortunately, benzodiazepines exert their effects not
through a single but through at least four different subtypes
of GABAA receptors enabling the pharmacological separa-
tion of different benzodiazepine effects. GABAA receptors
are heteropentameric chloride channels assembled from a
repertoire of α, β, γ, δ, ɛ, θ, π, and ρ subunits [14].
Benzodiazepine-sensitive GABAA receptors, which make
up the majority of GABAA receptors in the nervous system
including the spinal cord, are composed of two α (α1, α2,
α3 or α5) subunits, two β subunits, and one γ2 subunit.
All benzodiazepine-sensitive GABAA receptors contain a
conserved histidine residue in their extracellular N-terminal
domain, while the benzodiazepine-insensitive subunits (α4
and α6) carry an arginine at the same site [15]. Mutation of
this histidine residue renders GABAA receptor α subunits
diazepam-insensitive. The generation of so-called point
mutated or knock-in mice for all four benzodiazepine-
sensitive GABAA receptor α subunits (α1(H101R), α2
(H101R), α3(H126R), and α5(H105R)) by Rudolph and
Mohler [16] allowed to attribute the different in vivo
actions of benzodiazepines to molecularly defined GABAA
receptor subtypes (Fig. 1). Using these mice, it has become
possible to attribute the sedative effects of diazepam to
GABAA receptors containing the α1 subunit [17], while the
anxiolytic effects were mediated through the α2 GABAA
receptors [18]. Using these mice in models of inflammatory
and neuropathic pain, we were recently able to demonstrate
that the spinal antihyperalgesic effects of diazepam were
mediated mainly through GABAA receptors containing α2
subunit [13]. α1 subunits did not contribute significantly in
any of the pain models tested, while α3 and α5 subunits
showed some contribution depending on the pain model
used and the type of stimulus (heat, cold, or mechanical
stress) employed. Importantly, intrathecal treatment with
diazepam did not cause sedation and did not affect
responses of the non-inflamed or non-injured paw indicat-
ing that sedation or muscle relaxation were not major
confounding factors. Importantly, these results also indicat-
ed that the GABAA receptor subtypes responsible for
benzodiazepine-induced antihyperalgesia were different
from those that mediate sedation. This allowed the
investigation of possible antihyperalgesic actions of sys-
Fig. 1 Contribution of different
GABAA receptor subtypes to
benzodiazepine-mediated spinal
antihyperalgesia (A) and in
comparison to other desired or
undesired effects of classical
benzodiazepines (B). Data
modified from references [13],
[17], [18], [28], and [29]
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temic benzodiazepines in the absence of sedation either
through the analysis of mice carrying mutated α1 subunits
or through the use of so-called α1-sparing or non-sedative
benzodiazepine site ligands.
Both approaches yielded similarly positive results. A
recent study investigated the possible antihyperalgesic effect
of systemic diazepam in mice carrying point mutated α1
subunits (α1(H101R)) [19]. These mice displayed antihyper-
algesia in response to systemic diazepam virtually identical
to that seen in the corresponding wild-type mice but without
any signs of sedation. The same study also analyzed mice
which carried in addition to α1(H101R) a second
benzodiazepine-insensitive α subunit. Experiments in these
double point-mutated mice confirmed that α2 and α3
subunits were the most important subunits for diazepam-
mediated antihyperalgesia also after systemic treatment.
They also demonstrated that sedation and antihyperalgesia
exhibit a similar dose-dependence, which stresses the
problem of previous studies trying to distinguish antihyper-
algesia from confounding sedation. Finally, they showed that
the maximum levels of antihyperalgesia achievable with
diazepam either in wild-type mice after spinal application or
in α1(H101R) point-mutated mice after systemic application
were very similar suggesting that pronociceptive effects
arising from benzodiazepines at supraspinal sites are not of
major relevance after systemic treatment.
The results obtained in GABAA receptor point-mutated
mice provided the basis for the rational quest for
benzodiazepine-site ligands with a better side-effect profile.
Several subtype-selective compounds have been identified
and published in the recent years (Table 1). To test whether
such compounds would display antihyperalgesic efficacy after
systemic treatment, we tested as a proof-of-principle experi-
ment the α1-sparing (non-sedative) partial benzodiazepine-
site agonist L-838,417, which is an antagonist at the
benzodiazepine binding site of GABAA receptor α1 subunits
and a partial agonist at α2, α3, and α5 [20]. L-838,417 not
only reduced nociceptive withdrawal reflexes in behavioral
studies in rats, but also decreased pain-related brain activity
in functional magnetic resonance imaging (fMRI) experi-
ments evoked by stimulation of an inflamed hindpaw [13]
providing direct evidence that L-838,417 interfered with the
sensory and emotional components of pain (and not just with
nociceptive reflex activity). Similar antihyperalgesic effects
were achieved in the mouse formalin test with SL651498, a
full agonist at α2 and α3 subunits and a partial agonist at α1
and α5 subunits [21], by our group [19], and with NS11394,
which displays a functional specificity profile of α5 > α3 >
α2 > α1 [22], by a different laboratory [23] (Table 2).
NS11394 displayed an antihyperalgesic efficacy in neuro-
pathic pain models comparable to that achieved with
gabapentin, a drug frequently used for the treatment of
neuropathic pain in human patients. Data from this group
also suggest that not only are rather high doses of
benzodiazepines needed to yield sufficient antihyperalgesia
(comparable to those required for sedation and significantly
higher than anxiolytic doses) but also that a rather high
intrinsic activity is necessary. Bretazenil, a non-selective
Table 1 Subtype-selective benzodiazepine site ligands in comparison to diazepam
Compound Intrinsic activity at α1/α2/α3/α5 Major pharmacological activities Reference
Diazepam 0.71/0.81/0.88/0.57a Sedation, anxiolysis, motor impairment, muscle relaxation [31]
L-838,417 0.01/0.43/0.43/0.38a Anxiolysis, no sedation, no motor impairment [20]
SL651498 0.45/>1/0.83/0.50b Anxiolysis, muscle relaxation, no sedation [21]
TPA023 0/0.11/0.21/0.05c Anxiolysis, no sedation [27]
NS11394 0.078/0.26/0.52/0.78d Anxiolysis, no sedation, no motor impairment [22]
a Potentiation of GABA-induced currents in recombinant αx/βy/γ2 GABAA receptors at EC20 of GABA
bRelative to zolpidem (α1) or diazepam (α2, α3 and α5)
c Relative to chlordiazepoxide
d Relative to diazepam
Table 2 Effects of subtype-selective benzodiazepine site ligands on pain-related behavior
Compound Effects on pain-related behavior Reference
L-838,417 Antihyperalgesic against inflammatory and neuropathic pain, no effect on acute pain (heat and mechanical stimulation),
reduced hyperalgesia-related brain activity in fMRI experiments
[13]
SL651498 Reduced electrically evoked flexor reflexes, reduced flexor responses in the mouse formalin test [33], [19]
NS11394 No effect on acute pain in the hot plate test, reduced flexor responses in the formalin test, reduced capsaicin-induced
flexor responses, increased weight bearing on inflamed paw, reduced neuropathic pain (allodynia)
[23]
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agent with low intrinsic activity, was devoid of antihyper-
algesic effects in different pain models despite of good
anxiolytic activity [23]. Cases like that of bretazenil also
demonstrate that the in vivo specificity of subtype-selective
agents is determined not only by their subunit specificity but
also by other factors including intrinsic activity, active
metabolites, and pharmacokinetic properties such as on-set
and duration of action. These factors often limit the
comparability of data obtained with selective compounds or
with genetically modified mice.
Pharmacological and genetic evidence clearly indicates
that a genuine antihyperalgesic effect of benzodiazepines
exists after spinal as well as after systemic application—at
least in mice and rats. The two pertinent questions at
present are, can other unwanted effects besides sedation
also be avoided with subtype-selective (or partial) agonists
and does the concept of a benzodiazepine-mediated anti-
hyperalgesia also work in humans. Both questions are at
present difficult to answer. The latter one has to await the
availability of subtype-selective agents suitable for clinical
trials in humans. While L-838,417 possesses undesirable
pharmacokinetics in man [24], those of TPA023 and
SL651498 appear favorable [25, 26]. It is, however, not
yet clear whether these compounds would be suitable for
human pain studies. Possible caveats include the rather low
intrinsic activity of TPA023 [27] and remaining activity at
α1 subunits of SL651498 [21] which might cause signif-
icant sedation when given in antihyperalgesic doses.
The question whether other side effects apart from
sedation can be avoided with subtype-selective agents
should in principle be easier to answer but is also not yet
solved. Tolerance development (closely related to physical
dependence), reinforcing properties (related to addiction),
and memory impairment are probably the most relevant of
such side-effects. There is some reason to assume that
subtype-selective compounds should have a reduced risk
for these side effects. Data obtained in α1(H101R) point-
mutated mice indicate that potentiation of GABAA receptor
α1 subunits underlies also the amnestic effects of benzo-
diazepines [17]. However, hippocampus-dependent learn-
ing involves also α5 GABAA receptors [28], a finding
which is supported by the positive cognitive effects of
inverse agonists at α5 GABAA receptors [29]. Published
evidence suggests that physical dependence does not occur
with several α1-sparing agents (L-838,417, SL651498, and
TPA023) [30] and at least in the case of L-838,417,
tolerance against the antihyperalgesic effect was complete-
ly absent during a 9-day treatment period—in striking
contrast to morphine, which had lost its analgesic activity
already after 6 days [13]. However, besides subunit
specificity the lower intrinsic activity of these compounds
could also play a role [31], leaving it open whether
compounds with full intrinsic activity would retain this
advantage. The potential reinforcing properties appear
even more complex. High intrinsic activity at α1 GABAA
receptors clearly promotes reinforcing effects of benzodia-
zepines, but compounds devoid of activity at α1 (such as
L-838,417) still have some reinforcing potential [31] and
other factors apart from subunit specificity and intrinsic
activity such as a rapid onset of action in the CNS might
contribute as well [32].
In summary, recent evidence obtained either with
genetically modified mice or with subtype-selective benzo-
diazepine site ligands indicates that benzodiazepines pos-
sess significant antihyperalgesic activity. With classical
benzodiazepines, this antihyperalgesia requires a high
receptor occupancy leading to strong sedation and other
undesired effects which probably mask beneficial effects on
pain and which preclude their therapeutic use as analgesics.
Novel subtype-selective agents are in development which
should not only lack undesired sedation but might also be
devoid of other unwanted effects such as memory impair-
ment, physical dependence, and addiction. They will likely
possess anxiolytic and possibly muscle relaxant efficacy in
addition to antihyperalgesic properties.
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